12-O-Tetradecanoylphorbol-13-Acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder - Related Studies

12-O-Tetradecanoylphorbol-13-Acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder

This study has been completed.

Study NCT00004058. Last updated on November 16, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Leukemia
		Lymphoma
		Myelodysplastic Syndromes
		Precancerous/Nonmalignant Condition

2	Additional conditions recognized in this trial
		Bone Marrow Diseases
		Disease
		Multiple Myeloma
		Myelodysplastic-Myeloproliferative Diseases
		Myeloproliferative Disorders
		Neoplasms, Plasma Cell
		Precancerous Conditions
		Preleukemia
		Syndrome

3	More general conditions related to this trial
		Blood Protein Disorders
		Cardiovascular Diseases
		Hematologic Diseases
		Hemorrhagic Disorders
		Hemostatic Disorders
		Immune System Diseases
		Immunoproliferative Disorders
		Lymphatic Diseases
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type
		Paraproteinemias
		Pathologic Processes
		Vascular Diseases

4	Interventions listed in this trial
		tetradecanoylphorbol acetate

5	Sponsors listed in this trial
		Cancer Institute of New Jersey
		National Cancer Institute (NCI)